TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00548808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro low mixture
Description: Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
Study: NCT00860652

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiotherapy
Description: Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Early Salvage Radiotherapy
Description: Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
Study: NCT03499652

Intervention type: DIAGNOSTIC_TEST
Intervention: neonatal bacterial meningitis risk score
Description: In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision

Intervention type: DIAGNOSTIC_TEST
Intervention: neonatal bacterial meningitis risk score
Description: In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision
Study: NCT00428545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days
Study: NCT02081495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX reference product (Treatment A)
Description: Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX reference product (Treatment A)
Description: Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX test product (Treatment B)
Description: Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX test product (Treatment B)
Description: Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
Study: NCT03078998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Based Exercises
Description: Game based exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Based Exercises
Description: Game based exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Based Exercises
Description: Game based exercise
Study: NCT02995915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment
Description: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment
Description: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management
Description: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Monitoring
Description: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
Study: NCT02251665

Intervention type: OTHER
Intervention: No intervention
Description: a single-center prospective observational study
Study: NCT03354429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
Study: NCT04201288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavior Therapy (ABBT)
Description: Acceptance-Based Behavior Therapy (ABBT) In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified barriers to retention in care. Interventionists will help participants identify potential challenges to acceptance, including disclosure concerns. At the second session, participants will practice acceptance-based coping skills and a behavioral plan will be developed to target barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage their HIV.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced-Treatment-as-Usual (ETAU)
Description: ETAU will consist of two brief sessions lead by study interventionists, performed at the same times and by same methods as ABBT. Topics of education include safe sex practices, review of treatment options, and review of HIV-related indices of health.
Study: NCT04206111

Intervention type: PROCEDURE
Intervention: Preoxygenation
Description: preoxygenation with high flow nasal cannula at 40l/min for 5min
Study: NCT04465045

Intervention type: PROCEDURE
Intervention: Laparoscopy-hysteroscopy
Description: Under general anesthesia, we start by a first look in laparoscopy, to look for endometriosis mainly, tubal infertility, ovarian cysts or any abnormalities that may not have been suspected on the first exam. Then we check tubal patency after a look at the uterine cavity by hysteroscopy. Then we treat everything possible to treat to improve fertility, spontaneous or with ART.
Study: NCT00981500

Intervention type: PROCEDURE
Intervention: gastric bypass
Description: Roux-en-Y gastric bypass

Intervention type: PROCEDURE
Intervention: gastric banding
Description: laparoscopic adjustable gastric banding

Intervention type: PROCEDURE
Intervention: sleeve gastrectomy
Description: vertical sleeve gastrectomy
Study: NCT03862976

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: computerized cardiotocography
Description: computerized cardiotocography (C-CTG)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: computerized cardiotocography
Description: computerized cardiotocography (C-CTG)
Study: NCT02285985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets: 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets: 5mg
Study: NCT05552040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START NOW Group
Description: START NOW psychotherapy is a CBT, DBT and skills-based intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: START NOW Group
Description: START NOW psychotherapy is a CBT, DBT and skills-based intervention
Study: NCT02440880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone in addition to TAP block in dose of 4 mg
Description: Dexamethasone in addition to TAP block in dose of 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone in combination with TAP block in dose of 8 mg
Description: Dexamethasone in combination with TAP block in dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenous 4mg+ TAP block
Description: Dexamethasone intravenous in addition to TAP block in dose of 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenous in addition to TAP block in dose of 8 mg
Description: Dexamethasone intravenous + TAP block in dose of 8 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: TAP block without Dexamethasone neither intravenous nor in combination with the block
Study: NCT02111486

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakfast
Study: NCT00739336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention and Control
Description: The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
Study: NCT00912405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steroid-Eluting Sinexus Intranasal Splint
Description: Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
Study: NCT03746249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks
Study: NCT04453384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAV-19
Description: Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
Study: NCT03227380

Intervention type: OTHER
Group type: OTHER
Intervention: thoracic densitometry with contrast
Description: injected CT scan at 3 or 6 months after segmentectomy VATS
Study: NCT02077517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux en Y Gastric Bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux en Y Gastric Bypass
Study: NCT02571894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subclinical cardiotoxicity surveillance and treatment
Description: Intervention arm receives cardiology assessment and intervention.
Study: NCT04612491

Intervention type: BEHAVIORAL
Intervention: Pre-operative Consultation
Description: Pre-operative consultation will be given before Mohs surgery
Study: NCT01675713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Description: Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
Study: NCT01537341

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treadmill
Description: Participants will complete the intervention in 12-weeks, 3 times per week sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-belt
Description: Participants will complete the intervention in 12-weeks, 3 times per week sessions.
Study: NCT01645475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin lyophilisate (Melt)
Description: Patient receives Desmopressin lyophilisate (Melt).
Study: NCT03122912

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean Oil
Description: Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
Study: NCT02111265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: 1. Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~2. Cisatracurium is stopped before skin closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: 1. Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~2. Cisatracurium is stopped before skin closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index(BIS) monitor
Description: BiS is maintained at 40-60 during anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index(BIS) monitor
Description: BiS is maintained at 40-60 during anesthesia.
Study: NCT03642886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescribed Detraining
Description: Detraining is the deliberate act of reducing volume of exercise to observe subsequent changes in cardiac indices over time or the partial or complete loss of training of induced anatomical, physiological and performance adaptions. Detraining is primarily employed as a diagnostic tool to help differentiate Athletes' heart from cardiac pathology.
Study: NCT03933709

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Support System (NSS)
Description: Envelope 1 4.9g of Spirulina, 100mg ascorbic acid, 5mg folic acid and 10mg of glutamine. Was to be added to shake 1 during the first 10 days. Envelope 2 1g PUFAs n-3 and was to be added to shake 2 which was given throughout the intervention. Envelope 3 4.9g of Spirulina Maximum, 100mg ascorbic acid, 5mg folic acid, 5.2g vegetable protein, 125mg nicotinic acid, 50mg zinc, 100 mcg selenium and 800 UI cholecalciferol. Was to be added to shake 1 from day 11 until the end of week 6, after which it was suspended for 10 days and substituted for envelope 5 and then to be retaken until the end of the intervention. Envelope 4. 1g arginine and was to be added to shake 3 from day 8 until the end of the intervention. Envelope 5 contained the same ingredients as envelope 3 with an additional 10mg glutamine and was to be added to shake 1 from the start of week 7 for 10 days, after which envelope 3 was restarted. Probiotic at a dosage of 200 mg every 12 hours for 3 days at the beginning and week 6

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deworming
Description: nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deworming
Description: nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: recommended diet
Description: WHO Diet
Study: NCT02564172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMS group
Description: Conus medullaris stimulation with pentapolar surgical lead includes:~* Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~* Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~* If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~* If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OMM group
Description: Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~* at effective dose, and minimal effective dose on the basis of adverse events and contraindications~* as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches...) will not be forbidden or contra-indicated.
Study: NCT02493023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: navigated bronchoscopy
Study: NCT02502084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3NT flexible endoscope
Description: The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
Study: NCT02380716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® Ascending Stent Graft
Study: NCT02194959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer PN
Description: Navigation by Peer Patient Navigators

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pro PN
Description: Navigation by Standard Hospital Navigators
Study: NCT01018264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate (VESIcare)
Description: up to 10mg every day orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
Study: NCT00626977

Intervention type: DRUG
Intervention: ropivacaine
Description: 15 ml of ropivacaine 0.125% peridural once

Intervention type: DRUG
Intervention: ropivacaine and clonidine
Description: 15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
Study: NCT03294369

Intervention type: OTHER
Intervention: Observational
Description: This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
Study: NCT02772016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colla corii asini
Description: 15 g of Colla corii asini in powder form daily for 4 weeks
Study: NCT04455893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stratified Transplant Survival
Description: The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs. Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ. excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
Study: NCT04051840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic (Baxter Healthcare, Deerfield, IL, USA)
Description: ClinOleic group: Patients using ClinOleic or Structolipid-based lipid parenteral nutrition regimen. From day 0 to day 5, the goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid.
Study: NCT01041807

Intervention type: DRUG
Intervention: amlodipine/losartan
Description: amlodipine/losartan (COZAAR XQ) prescribed according to the current local label